I
I-Derm
I Derm Pharma is developing a first-in-class oral therapy for psoriasis and other autoimmune skin inflammatory diseases.
About
I-Derm develops a new nonsteroidal topical treatment for inflammatory skin diseases based on a novel mechanism of action. This mechanism directly targets cutaneous elements rather than the immune system and is therefore uniquely function only on the skin. This novel treatment will be the first nonsteroidal topical treatments for psoriasis.
Technology stack
detected 2026-06-18Est. monthly stack spend~$170/mo
Email
Microsoft 365
Stack
Wix
Observability
Sentry
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does I-Derm do?
I-Derm develops a new nonsteroidal topical treatment for inflammatory skin diseases based on a novel mechanism of action. This mechanism directly targets cutaneous elements rather than the immune system and is therefore uniquely function only on the skin. This novel treatment will be the first nonsteroidal topical treatments for psoriasis.
Where is I-Derm headquartered?
I-Derm is headquartered in Tel Aviv, Israel.
When was I-Derm founded?
I-Derm was founded in 2022.
What industry does I-Derm operate in?
I-Derm operates in Life Sciences.